The presentation will be accessible via a Webcast through a link posted on the Investors, Events Calendar section of the Nektar website: http://ir.nektar.com/events.cfm. In addition, the company will webcast the Q&A breakout session immediately following its presentation at 11:30 a.m. Pacific Time. This Webcast will be available for replay until February 20, 2018.
Nektar Therapeutics is a research-based, development stage biopharmaceutical company whose mission is to discover and develop innovative medicines to address the unmet medical needs of patients. Our R&D pipeline of new investigational medicines includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar's proprietary and proven chemistry platform in the discovery and design of our new therapeutic candidates. Nektar is headquartered in San Francisco, California, with additional operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.
Jennifer Ruddock of Nektar Therapeutics
View original content:http://www.prnewswire.com/news-releases/nektar-therapeutics-president-and-ceo-howard-robin-to-present-at-the-36th-annual-jp-morgan-healthcare-conference-in-san-francisco-ca-300576786.html
News Provided by Acquire Media